Conference Reports for NATAP

(APASL) 23rd Conference of the Asian Pacific Association for the Study of the Liver 6-9 June 2013, Singapore Back

FALDAPREVIR PLUS PEGYLATED-INTERFERON AND RIBAVIRIN IN CHRONIC HCV GENOTYPE-1 TREATMENT-NAïVE PATIENTS: SUBANALYSIS OF PATIENTS FROM JAPAN, TAIWAN AND SOUTH KOREA       Reported by Jules Levin APASL Liver Week, Singapore, 6-9 June 2013   M Omata1, S Nishiguchi2, J-H Kao3, M ChO4, DM Jensen5, P Ferenci6, WO Bocher7, F Voss7, AM Quinson8 and JO Stern8   1Yamanashi Central and Kita Hospitals, Yamanashi, Japan; 2Hyogo College of Medicine, Hyogo, Japan; 3National Taiwan University Hospital, Taipei, Taiwan; 4Pusan National University Yangsan Hospital, Busan, Korea; 5University of Chicago Medical Center, Chicago, IL, USA; 6Medical University of Vienna, Vienna, Austria; 7Boehringer Ingelheim Pharmaceuticals GmbH & Co KG, Ingelheim, Germany; 8Boehringer Ingelheim Pharmaceuticals Inc, Ridgefield, CT, USA.